CY1106802T1 - Ανασταλτικη της εκκρισης γαστρικου οξεος συνθεση - Google Patents
Ανασταλτικη της εκκρισης γαστρικου οξεος συνθεσηInfo
- Publication number
- CY1106802T1 CY1106802T1 CY20071101056T CY071101056T CY1106802T1 CY 1106802 T1 CY1106802 T1 CY 1106802T1 CY 20071101056 T CY20071101056 T CY 20071101056T CY 071101056 T CY071101056 T CY 071101056T CY 1106802 T1 CY1106802 T1 CY 1106802T1
- Authority
- CY
- Cyprus
- Prior art keywords
- dosage form
- acid secretion
- gastric acid
- inhibitor composition
- secretion inhibitor
- Prior art date
Links
- 230000027119 gastric acid secretion Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010019375 Helicobacter infections Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 1
- 239000000612 proton pump inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Στην παρούσα περιγράφεται μια από του στόματος φαρμακευτική δοσολογική μορφή περιέχουσα φαρμακολογικώς αποτελεσματικές ποσότητες από έναν οξυευαίσθητο αναστολέα της αντλίας πρωτονίων ή ένα άλας αυτού, έναν ανταγωνιστή υποδοχέα Η2 ή ένα άλας αυτού και έναν φαρμακευτικώς αποδεκτό φορέα. Η δοσολογική μορφή είναι ικανή αύξησης του γαστρικού pΗ πάνω από 4 εντός δύο ωρών μετά τη χορήγηση και διατήρησης του σε αυτό το επίπεδο επί τουλάχιστον 4 ώρες. Επίσης περιγράφεται μια μέθοδος παρασκευής της δοσολογικής μορφής, η χρήση της στη θεραπεία της δυσπεψίας και της μόλυνσης από Ελικοβακτήριο του πυλωρού (Helicobacter pylori), και μια μέθοδος θεραπείας διαταραχών που συνδέονται με έκκριση γαστρικού οξέος.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101379A SE0101379D0 (sv) | 2001-04-18 | 2001-04-18 | Komposition som hämmar utsöndring av magsyra |
PCT/SE2002/000757 WO2002083132A1 (en) | 2001-04-18 | 2002-04-17 | Gastric acid secretion inhibiting composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106802T1 true CY1106802T1 (el) | 2012-05-23 |
Family
ID=20283818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071101056T CY1106802T1 (el) | 2001-04-18 | 2007-08-07 | Ανασταλτικη της εκκρισης γαστρικου οξεος συνθεση |
Country Status (14)
Country | Link |
---|---|
US (3) | US7815940B2 (el) |
EP (3) | EP1389109B1 (el) |
CN (1) | CN1236770C (el) |
AT (1) | ATE363282T1 (el) |
AU (1) | AU2002253768B2 (el) |
CA (1) | CA2444268A1 (el) |
CY (1) | CY1106802T1 (el) |
DE (1) | DE60220403T2 (el) |
DK (1) | DK1389109T3 (el) |
ES (1) | ES2290285T3 (el) |
NZ (1) | NZ528475A (el) |
PT (1) | PT1389109E (el) |
SE (1) | SE0101379D0 (el) |
WO (1) | WO2002083132A1 (el) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0101379D0 (sv) | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
CA2537182A1 (en) * | 2003-08-29 | 2005-03-10 | Dynogen Pharmaceuticals, Inc. | Compositions useful for treating gastrointestinal motility disorders |
ATE380355T1 (de) * | 2004-01-26 | 2007-12-15 | Draka Comteq Bv | Hüllrohrwindung zur ankopplung eines faseroptischen kabels und methode zur installation eines faseroptischen kabels |
WO2005074931A1 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Pharmaceutical combinations comprising (s) -pantoprazole |
CA2569833A1 (en) * | 2004-04-30 | 2005-11-10 | Altana Pharma Ag | Method of classifying gerd |
WO2006026337A1 (en) * | 2004-08-25 | 2006-03-09 | Fairfield Clinical Trials, Llc | Combination of a proton pump inhibitor and a h2 antagonist for the treatment of gastroesophageal reflux disease |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US8029441B2 (en) | 2006-02-28 | 2011-10-04 | Abbott Diabetes Care Inc. | Analyte sensor transmitter unit configuration for a data monitoring and management system |
WO2009105568A1 (en) | 2008-02-20 | 2009-08-27 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
WO2009145905A1 (en) * | 2008-05-30 | 2009-12-03 | Pozen Inc. | Dosage forms for the rapid and sustained elevation of gastric ph |
CN102209529A (zh) | 2008-09-09 | 2011-10-05 | 阿斯利康(瑞典)有限公司 | 将药物组合物递送至有需要的患者的方法 |
US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
KR20120030106A (ko) | 2009-06-25 | 2012-03-27 | 아스트라제네카 아베 | Nsaid-연관된 궤양의 발생 위험이 있는 환자의 치료 방법 |
CA2766524A1 (en) * | 2009-06-25 | 2010-12-29 | Pozen Inc. | Method for treating a patient in need of aspirin therapy |
CN102473276B (zh) | 2009-08-31 | 2016-04-13 | 雅培糖尿病护理公司 | 医疗装置及方法 |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2519229A2 (en) | 2009-12-29 | 2012-11-07 | Novartis AG | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080500A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
LT3766408T (lt) | 2010-03-24 | 2022-07-11 | Abbott Diabetes Care, Inc. | Medicinos prietaiso įvedikliai |
EP4344633A2 (en) | 2011-12-11 | 2024-04-03 | Abbott Diabetes Care, Inc. | Analyte sensor methods |
MX2014007935A (es) | 2011-12-28 | 2014-11-14 | Pozen Inc | Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico. |
WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
CA2984939A1 (en) | 2015-05-14 | 2016-11-17 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
EP3162371A1 (en) * | 2015-10-27 | 2017-05-03 | Przemyslaw Taciak | A composition comprising simethicone, gastric acid-neutralizing substances and gastric enzyme(s) (e.g. pancreatine) for use in the treatment of digestive disorders |
EP4119042B1 (en) | 2015-12-30 | 2023-09-13 | Dexcom, Inc. | Transcutaneous analyte sensor systems |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CN110461217B (zh) | 2017-01-23 | 2022-09-16 | 雅培糖尿病护理公司 | 用于分析物传感器插入的系统、装置和方法 |
EP3928688B1 (en) | 2017-06-23 | 2022-06-01 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and needle hub comprising anti-rotation feature |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
WO2019083939A1 (en) | 2017-10-24 | 2019-05-02 | Dexcom, Inc. | PRECONNECTED ANALYTE SENSORS |
USD926325S1 (en) | 2018-06-22 | 2021-07-27 | Dexcom, Inc. | Wearable medical monitoring device |
USD1002852S1 (en) | 2019-06-06 | 2023-10-24 | Abbott Diabetes Care Inc. | Analyte sensor device |
USD999913S1 (en) | 2020-12-21 | 2023-09-26 | Abbott Diabetes Care Inc | Analyte sensor inserter |
CN113425717B (zh) * | 2021-04-22 | 2023-06-16 | 成都欧林生物科技股份有限公司 | 一种提高口服幽门螺杆菌疫苗效力的药剂及其应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
JPS6056143B2 (ja) * | 1979-08-02 | 1985-12-09 | 山之内製薬株式会社 | アミジン誘導体ならびにその製造法 |
IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
GB8809421D0 (en) | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
US5204118A (en) * | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
AU649456B2 (en) | 1990-06-20 | 1994-05-26 | Astra Aktiebolag | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
US5244670A (en) | 1991-04-04 | 1993-09-14 | The Procter & Gamble Company | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress |
CA2125579C (en) * | 1991-12-17 | 2005-06-21 | Richard C. Fuisz | Ulcer prevention treatment composition and method |
SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
AU7218294A (en) * | 1993-07-06 | 1995-02-06 | Mcneil-Ppc, Inc. | H2 antagonist-alginate combinations |
SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
WO1995017080A1 (en) | 1993-12-14 | 1995-06-22 | Neo-Concepts, Inc. | Solid state power supply circuit for cold cathode lighting |
US5407687A (en) | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
US6132768A (en) * | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) * | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
SE9600071D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
SE9600072D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
US6949264B1 (en) * | 1996-11-27 | 2005-09-27 | Wm. Wrigley Jr. Company | Nutraceuticals or nutritional supplements and method of making |
DE19709897A1 (de) * | 1997-03-11 | 1998-09-17 | Hoechst Ag | Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel |
SE9700885D0 (sv) * | 1997-03-12 | 1997-03-12 | Astra Ab | New pharmaceutical formulation |
SK932000A3 (en) | 1997-07-22 | 2000-09-12 | Merck & Co Inc | USE OF BIPHOSPHONATE FOR INHIBITING BONE RESORPTION,ì (54) PHARMACEUTICAL COMPOSITION CONTAINING SAME AND A KIT |
US6013680A (en) * | 1997-10-21 | 2000-01-11 | Amano Pharmaceutical Co., Ltd. | Digestive enzyme-containing medicament |
FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
JP2000063280A (ja) | 1998-06-11 | 2000-02-29 | Takeda Chem Ind Ltd | 抗ヘリコバクタ―・ピロリ活性胃腸薬 |
SI1105105T1 (sl) | 1998-08-12 | 2006-08-31 | Altana Pharma Ag | Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole |
ATE235247T1 (de) * | 1998-10-06 | 2003-04-15 | Mars Uk Ltd | Verhaltensstörungen beim tier |
US6852739B1 (en) * | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
DE19925710C2 (de) | 1999-06-07 | 2002-10-10 | Byk Gulden Lomberg Chem Fab | Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer |
IL130602A0 (en) | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
US6316469B1 (en) * | 2000-03-01 | 2001-11-13 | Duke University | Use of selective serotonin reuptake inhibitors for treatment of chest pain of non-cardiac origin and gastro-esophageal reflux disease |
SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
-
2001
- 2001-04-18 SE SE0101379A patent/SE0101379D0/xx unknown
-
2002
- 2002-04-17 US US10/475,254 patent/US7815940B2/en not_active Expired - Fee Related
- 2002-04-17 EP EP02723029A patent/EP1389109B1/en not_active Expired - Lifetime
- 2002-04-17 AU AU2002253768A patent/AU2002253768B2/en not_active Ceased
- 2002-04-17 EP EP06076646A patent/EP1731141A3/en not_active Withdrawn
- 2002-04-17 CA CA002444268A patent/CA2444268A1/en not_active Abandoned
- 2002-04-17 ES ES02723029T patent/ES2290285T3/es not_active Expired - Lifetime
- 2002-04-17 AT AT02723029T patent/ATE363282T1/de active
- 2002-04-17 CN CNB028083784A patent/CN1236770C/zh not_active Expired - Fee Related
- 2002-04-17 EP EP10075409A patent/EP2253309A3/en not_active Withdrawn
- 2002-04-17 PT PT02723029T patent/PT1389109E/pt unknown
- 2002-04-17 DE DE60220403T patent/DE60220403T2/de not_active Expired - Lifetime
- 2002-04-17 DK DK02723029T patent/DK1389109T3/da active
- 2002-04-17 NZ NZ528475A patent/NZ528475A/en not_active IP Right Cessation
- 2002-04-17 WO PCT/SE2002/000757 patent/WO2002083132A1/en active IP Right Grant
-
2007
- 2007-07-06 US US11/822,502 patent/US20080031941A1/en not_active Abandoned
- 2007-08-07 CY CY20071101056T patent/CY1106802T1/el unknown
-
2010
- 2010-07-12 US US12/803,982 patent/US20110104264A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7815940B2 (en) | 2010-10-19 |
EP1389109B1 (en) | 2007-05-30 |
DK1389109T3 (da) | 2007-07-16 |
DE60220403T2 (de) | 2008-01-24 |
SE0101379D0 (sv) | 2001-04-18 |
AU2002253768B2 (en) | 2006-08-17 |
US20110104264A1 (en) | 2011-05-05 |
ATE363282T1 (de) | 2007-06-15 |
EP1389109A1 (en) | 2004-02-18 |
CN1236770C (zh) | 2006-01-18 |
DE60220403D1 (de) | 2007-07-12 |
EP1731141A3 (en) | 2009-09-02 |
US20080031941A1 (en) | 2008-02-07 |
US20040131674A1 (en) | 2004-07-08 |
EP1731141A2 (en) | 2006-12-13 |
CN1503670A (zh) | 2004-06-09 |
EP2253309A2 (en) | 2010-11-24 |
WO2002083132A1 (en) | 2002-10-24 |
ES2290285T3 (es) | 2008-02-16 |
CA2444268A1 (en) | 2002-10-24 |
NZ528475A (en) | 2004-08-27 |
EP2253309A3 (en) | 2011-03-09 |
PT1389109E (pt) | 2007-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106802T1 (el) | Ανασταλτικη της εκκρισης γαστρικου οξεος συνθεση | |
CY1117470T1 (el) | Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση | |
CY1112260T1 (el) | Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης | |
NO20052019L (no) | Blanding for a inhibere sekresjon av magesyre | |
CY1112606T1 (el) | Διαλυμα αριπριπραζολης για χορηγηση εκ του στοματος | |
CY1106727T1 (el) | Ινδανυλ παραγωγα για την αντιμετωπιση ασθενειων αεραγωγων | |
ES2086643T3 (es) | Derivados de camptotecina solubles en agua. | |
CY1114708T1 (el) | Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης | |
CY1111880T1 (el) | Βελτιωμενο διαδερμικο θεραπευτικο συστημα για την αγωγη της νοσου του parkinson | |
CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
LU92323I2 (fr) | La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate | |
BR0113757A (pt) | Derivados de quinolinona como inibibores de tirosina quinase | |
RU2006130000A (ru) | Органические соединения | |
DK1487829T3 (da) | Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte | |
CY1105047T1 (el) | Ενωσεις πυριδοπυριμιδινονης, η μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τις περιεχουν | |
CY1106763T1 (el) | Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου | |
NO20052100L (no) | Raloksifensalt I | |
CY1108625T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση απο το στομα ηπαρινης ή παραγωγων της | |
CY1109939T1 (el) | Εκ του στοματος χορηγουμενη μορφη δοσολογιας για ελεγχομενη αποδεσμευση φαρμακου | |
EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
DK1039900T3 (da) | Farmaceutisk præparat indeholdende sibutramin og orlistat | |
DE60030283D1 (de) | Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen | |
ATE339202T1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
EA200101179A1 (ru) | Полиморфные модификации кристаллического (2-бензгидрил-1-азабицикло[2.2.2]окт-3-ил)-(5-изопропил-2-метоксибензил)-аммония хлорида в качестве антагонистов рецептора нейрокинина 1 (nk-1) |